导师风采
张太平

个人信息

Personal Information

  • 性别:男
  • 导师类型:博导
  • 职称:主任医师
  • 该职称任职时间:19950720

联系方式

Contact Information

  • 所属院系:北京协和医院
  • 所属专业:
  • 邮箱 : tpingzhang@yahoo.com
  • 工作电话 : 13520132976

个人简介

Personal Profile

张太平,男,北京协和医院基本外科教授,主任医师,博士生导师。1995年获中国协和医科大学外科学博士学位,2002年4月在美国匹兹堡大学Starzl器官移植研究所做访问学者,2002年5月至2004年12月在美国北卡罗来纳大学基因治疗中心做博士后研究。目前担任中国研究型医院学会胰腺疾病专业委员会主任委员,中国研究型医院学会加速康复外科医学专业委员会副主任委员;中国研究型医院学会普通外科分会副主任委员;中国医师协会胰腺病学专业委员会副主任委员;中华医学会外科学分会常委兼副秘书长;外科手术学组副组长;美国外科学院会员(FACS);国际外科学会会员。《中华肝胆外科杂志》、《中华胰腺病学杂志》、《中华普通外科手术学杂志电子版》和《中华肝脏外科手术学电子杂志》副主编,《中华外科杂志》、《中华普通外科杂志》、《中华消化外科杂志》、《中国实用外科杂志》、《外科理论与实践》、《临床肝胆病杂志》、《中华疝与腹壁外科杂志电子版》、《国际外科杂志》等杂志编委。《Annals of Surgical Oncology》、《中华医学杂志》、《中华外科杂志》特约审稿专家。国家自然科学基金、科技部支撑计划、首发基金、教育部留学基金、人事部留学基金评审专家。擅长胰腺、胃肠、胆道、甲状腺疾病尤其是复杂的胰腺癌、胰腺神经内分泌肿瘤、胰腺囊性肿瘤等病例的外科诊治。长期从事胰腺外科的临床与基础研究,主要研究方向为胰腺癌早期诊断和化疗耐药,获得国家十二五科技支撑项目、973、国家自然科学基金、教育部博士点基金等多项基金资助。发表论文及综述300余篇,参加专著和教材编写30余部,作为主编助理出版的《胰腺病学》获国家新闻出版署优秀图书出版工程,以第二和第三完成人获得国家科技进步二等奖各一项、北京市科技进步一等奖、中华医学科技奖一等奖、教育部科技进步二等奖等国家级、省部级奖励10余项。

团队简介

Team Profile

申请人在赵玉沛院士带领下,长期从事胰腺疾病的基础与临床研究,先后获得国家科技支撑计划、973项目、国家重点研发计划等项目资助,构建了包括胰腺癌PDX模型、类器官药筛平台、个体化条件重编程等在内的胰腺癌体外药筛体系及化疗耐药分子调控网络,探索了胰腺癌化疗耐药机制和治疗靶点,在 Journal of Hematology & Oncology、Molecular Cancer、Clinical Cancer Research、Annals of Surgery等国内外期刊发表论文 300余篇,获得发明专利授权 5项。以第二和第三完成人先后获国家科技进步二等奖两次,以及中华医学科技一等奖、教育部科技成果二等奖和北京市科技成果一等奖等国家级、省部级奖励 10余项。围绕胰腺疾病的临床诊治,申请人牵头了多项多中心临床研究,在胰腺癌新辅助治疗、辅助治疗、胰腺围术期管理等多个方面积累了丰富的研究经验,研究成果被相关指南引用。作为国内胰腺疾病领域的知名专家,担任中国研究型医院学会胰腺疾病专委会主任委员、中华医学会外科学分会常委兼副秘书长及手术学组副组长、中国医师协会胰腺病专委会副主任委员、中华肝胆外科杂志和中华胰腺病学杂志副主编,先后牵头和执笔指南及专家共识近 10部,涵盖了胰腺疾病诊断、手术治疗、围术期管理、胰腺癌新辅助治疗等多个方面,推动了我国胰腺疾病诊治的规范化。申请人先后参与教材及专著编写 30余部,培养各类研究生、博士后 50余人。

  • 研究方向Research Directions
胰腺疾病的基础与临床研究
  • 在校研究生Current Graduate Students

硕士研究生 2 名,博士研究生 6 名

  • 科研项目Research Projects
# 项目名称 起止日期 金额 项目类型 本人角色
1PGM3 抑制剂作为胰腺导管腺癌创新疗法的临床前评估2020-01-01 —— 2022-12-31180.0主持在研的国家或省部级科研项目主持者
2MYC/let-7/LAT2通路通过谷氨酰胺代谢和糖酵解调控胰腺癌化疗耐药的机制研究2020-01-01 —— 2023-12-0155.0主持在研的国家或省部级科研项目主持者
3PGM3抑制剂作为胰腺导管腺癌创新疗法的临床前评估2020-01-01 —— 2022-12-01主持在研的国家或省部级科研项目主持人
4国产腔镜手术机器人系统肝胆胰外科临床应用解决方案2023-11-05 —— 2026-10-01主持在研的国家或省部级科研项目主持人
5探究胰腺癌“空间-动态”化疗耐药机制及治疗靶点的研究2023-01-01 —— 2026-12-31主持在研的国家或省部级科研项目主持人
6MYC/let-7/LAT2通路通过谷氨酰胺代谢和糖酵解调控胰腺癌化疗耐药的机制研究2020-01-01 —— 2023-12-01主持在研的国家或省部级科研项目主持人
7基于PDTX模型筛选的lncRNAs在胰腺癌化疗耐药调控网络中的作用及机制研究2018-01-01 —— 2021-12-31主持在研的国家或省部级科研项目主持人
8靶向let-7/LAT2/mTOR联合PD-L1单抗对胰腺癌免疫治疗的机制研究2019-01-15 —— 2021-12-15主持在研的国家或省部级科研项目主持人
9RARS2-MFN1-BCL2轴通 过调控线粒体动力学介 导胰腺癌化疗耐药的机 制研究2024-01-01 —— 2026-12-31主持在研的国家或省部级科研项目主持人
103D生物打印类器官药筛在胰腺癌辅助化疗中的临床应用2022-11-01 —— 2025-11-01主持在研的国家或省部级科研项目主持人
11生物3D打印高通量肿瘤类器官技术开发及临床转化研究2023-09-30 —— 2026-09-30主持在研的国家或省部级科研项目主持人
12基于i-CR的胰腺癌快速药筛体系的临床应用2019-11-01 —— 2021-10-01主持的企业/行业委托重大项目主持人
13基于视频的基本外科阶梯式临床及微创教学方案2021-07-01 —— 2023-12-31主持的企业/行业委托重大项目主持人
14基于 i-CR 的胰腺癌快速药筛体系的临床应用2019-11-01 —— 2021-10-31主持的企业/行业委托重大项目主持人
  • 发表论文Papers
# 论文题目 期刊名称 发表年份 论文署名
1Do novel treatment strategies enhance T cell-mediated Immunity: Opportunities and challenges in pancreatic cancer immunotherapyInt Immunopharmacol2022-06-10张太平
2Prognostic and predictive value of a five-molecule panel in resected pancreatic ductal adenocarcinoma: A multicentre studyEBioMedicine2022-06-10张太平
3"The Role of Mitochondria in the Chemoresistance of Pancreatic Cancer Cells"Cells2022-06-11张太平
4Activator protein 1 promotes gemcitabine-induced apoptosis in pancreatic cancer by upregulating its downstream target BimOncol Lett2022-06-11张太平
5Extracellular vesicles as mediators of the progression and chemoresistance of pancreatic cancer and their potential clinical applications.molecular cancer2022-06-11张太平
6Expression of key mTOR pathway components in pancreatic ductal adenocarcinoma: A multicenter study for clinicopathologic and prognostic significanceCancer Lett2022-06-11张太平
7WT1-associated protein is a novel prognostic factor in pancreatic ductal adenocarcinomaOncol Lett2022-06-11张太平
8Hexosamine Pathway Inhibition Overcomes Pancreatic Cancer Resistance to Gemcitabine Through Unfolded Protein Response and EGFR-Akt Pathway ModulationOncogene2022-06-10张太平
9OLR1 Promotes Pancreatic Cancer Metastasis via Increased c-Myc Expression and Transcription of HMGA2Mol Cancer Res.2022-06-11张太平
10High expression of GRK3 is associated with favorable prognosis in pancreatic ductal adenocarcinoma.Pathology - Research and Practice2022-06-11张太平
11PIM-1 contributes to the malignancy of pancreatic cancer and displays diagnostic and prognostic valueJournal of Experimental & Clinical Cancer Research2022-06-11张太平
12"Changes in Serum Lactate Level Predict Postoperative Intra- Abdominal Infection After Pancreatic Resection"World J Surg2022-06-11张太平
13"The dual functional role of MicroRNA?18a (miR?18a) in cancer development"Clin Trans Med2022-06-11张太平
14A Single Talent Immunogenic Membrane Antigen and Novel Prognostic Predictor: voltage-dependent anion channel 1 (VDAC1) in Pancreatic Cancer.Sci Rep2022-06-11张太平
15Analysis of clinical characteristics and treatment of pancreatic cystic tumorsChin J Cancer Res2022-06-11张太平
16Primary Retroperitoneal Ganglioneuroma: A Retrospective Cohort Study of 32 PatientsFront Surg2022-06-11张太平
17"Do novel treatment strategies enhance T cell- mediated Immunity: Opportunities and challenges in pancreatic cancer immunotherapy"Int Immunopharmacol2022-06-11张太平
18A randomised, multicentre trial of somatostatin to prevent clinically relevant postoperative pancreatic fistula in intermediaterisk patients after pancreaticoduodenectomyJ Gastroenterol2022-06-13张太平
19The prospect of serum and glucocorticoid-inducible kinase 1 (SGK1) in cancer therapy: a rising starTher Adv Med Oncol2022-06-10张太平
20"Suppression of the HBP Function Increases Pancreatic Cancer Cell Sensitivity to a Pan-RAS Inhibitor"Cells2022-06-11张太平
21NF-kB in pancreatic cancer: Its key role in chemoresistanceCancer Letters2022-06-11张太平
22High-resolution Hi-C maps highlight multiscale 3D epigenome reprogramming during pancreatic cancer metastasisJ Hematol Oncol.2022-06-13张太平
23Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer. J Hematol Oncol.2022-06-11张太平
24Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft ModelsClin Cancer Res2022-06-11张太平
25The?enhancement?of?glycolysis?regulates?pancreatic?cancer?metastasis.Cellular and Molecular Life Sciences2022-06-11张太平
26"Role of the microbiome in occurrence, development and treatment of pancreatic cancer"molecular cancer2022-06-11张太平
275-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers.Cell Res2022-06-11张太平
28Surgeons’ knowledge regarding the diagnosis and management of pancreatic cancer in China: a cross-sectional studyBMC Health Serv Res2022-06-11张太平
29Prognostic relevance of UCH-L1 and α-internexin in pancreatic neuroendocrine tumors.Sci Rep2022-06-11张太平
30Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft ModelsClin Cancer Res2022-06-11张太平
31Current epidemiology of pancreatic cancer: Challenges and opportunitiesChin J Cancer Res2022-06-11张太平
32Novel Discoveries Targeting Pathogenic Gut Microbes and New Therapies in Pancreatic Cancer: Does Pathogenic E. coli Infection Cause Pancreatic Cancer Progression Modulated by TUBB/Rho/ROCK Signaling Pathway? A Bioinformatic AnalysisBiomed Res Int.2022-06-10张太平
33Expression, function and clinical application of stanniocalcin-1 in cancerJ Cell Mol Med2022-06-10张太平
34PD-1/PD-L1 and immunotherapy for pancreatic cancerCancer Lett 2022-06-11张太平
35The underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancerCancer Lett 2022-06-11张太平
36MicroRNA-1285 inhibits malignant biological behaviors of human pancreatic cancer cells by negative regulation of YAP1.Neoplasma 2022-06-11张太平
37"Novel therapies targeting hypoxia mechanism to treat pancreatic cancer"Chin J Cancer Res2022-06-11张太平
38"Comprehensive Analysis of Autophagy-Associated lncRNAs Reveal Potential Prognostic Prediction in Pancreatic Cancer"Front Oncol.2022-06-11张太平
39"Risk factors and prevention of postoperative pancreatic fistula after insulinoma enucleation:a retrospective study from a high-volume center"Pancreatology2022-06-11张太平
40"Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine"Journal of Experimental & Clinical Cancer Research2022-06-11张太平
41"Radical antegrade modular pancreatosplenectomy (RAMPS) versus conventional distal pancreatosplenectomy (CDPS) for left-sided pancreatic ductal adenocarcinoma"Surg Today2022-06-11张太平
42"Pancreatic head cancer: Open or minimally invasive pancreaticoduodenectomy?"Chinese Journal of Cancer Research2022-06-11张太平
43MiR-135a biogenesis and regulation in malignancy: a new hope for cancer research and therapyCancer Biol Med2022-06-10张太平
44Is Invagination Anastomosis More Effective in Reducing Clinically Relevant Pancreatic Fistula for Soft Pancreas After Pancreaticoduodenectomy Under Novel Fistula Criteria: A Systematic Review and Meta-AnalysisFront Oncol.2022-06-10张太平
45Mechanistic Target of Rapamycin in the Tumor Microenvironment and Its Potential as a Therapeutic Target for Pancreatic CancerCancer Lett. 2022-06-11张太平
46 Novel therapeutic strategies and perspectives for metastatic pancreatic cancer: vaccine therapy is more than just a theory.Cancer Cell Int.2022-06-11张太平
47Plasma miRNAs Effectively Distinguish Patients With Pancreatic Cancer From Controls: A Multicenter StudyAnn Surg2022-06-11张太平
48MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma,Journal of Experimental & Clinical Cancer Research2022-06-11张太平
49MicroRNA-27a (miR-27a) in Solid Tumors: A Review Based on Mechanisms and Clinical Observations.Frontiers in Oncology2022-06-11张太平
50Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC)Cancer Lett. 2022-06-10张太平
51Targeting hypoxic tumor microenvironment in pancreatic cancerJ Hematol Oncol.2022-06-11张太平
52MicroRNA-381-A Key Transcriptional Regulator: Its Biological Function and Clinical Application Prospects in CancerFront Oncol.2022-06-11张太平
53Novel discoveries targeting gemcitabine‐based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination?Cancer Medicine.2022-06-11张太平
54CREPT serves as a biomarker of poor survival in pancreatic ductal adenocarcinomaCellular Oncology2022-06-11张太平
55LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancerJournal of Experimental & Clinical Cancer Research2022-06-11张太平
56Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer.Journal of Hematology & Oncology2019-08-16通讯作者
57OLR1 Promotes Pancreatic Cancer Metastasis via Increased c-Myc Expression and Transcription of HMGA2MOLECULAR CANCER RESEARCH2020-05-01通讯作者
58Prognostic and predictive value of a five-molecule panel in resected pancreatic ductal adenocarcinoma: A multicentre studyEBioMedicine2020-04-28通讯作者
59Novel Discoveries Targeting Pathogenic Gut Microbes and New Therapies in Pancreatic Cancer: Does Pathogenic E. coli Infection Cause Pancreatic Cancer Progression Modulated byBiomed Research International2020-05-11通讯作者
60CREPT serves as a biomarker of poor survival in pancreatic ductal adenocarcinomaCellular Oncology2020-10-01通讯作者
61Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft ModelsCLINICAL CANCER RESEARCH2021-06-13通讯作者
62HIF-1α-regulated stanniocalcin-1 mediates gemcitabine resistance in pancreatic ductal adenocarcinoma via PI3K/AKT signaling pathwayMOLECULAR CARCINOGENESIS2022-07-04通讯作者
63High-resolution Hi-C maps highlight multiscale 3D epigenome reprogramming during pancreatic cancer metastasisJournal of Hematology & Oncology2021-08-04通讯作者
64A randomised, multicentre trial of somatostatin to prevent clinically relevant postoperative pancreatic fistula in intermediaterisk patients after pancreaticoduodenectomyJOURNAL OF GASTROENTEROLOGY2021-08-28通讯作者
65Identification and Validation of Constructing the Prognostic Model With Four DNA Methylation-Driven Genes in Pancreatic Cancerfrontiers in cell and developmental biology2021-09-07通讯作者
66Comprehensive Analysis of Autophagy-Associated lncRNAs Reveal Potential Prognostic Prediction in Pancreatic CanceFrontiers in Oncology2021-05-07通讯作者
67Using a microRNA panel of circulating exosomes for diagnosis of pancreatic cancer: multicentre case-control studyBRITISH JOURNAL OF SURGERY2022-11-11通讯作者
68Cancer-specific survival and metastasis in pancreatic mucinous cystadenocarcinoma: A SEER-based cohort studyFrontiers in Oncology2022-10-20通讯作者
69mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and immune microenvironment remodeling in Trp53flox/ +LSL-KrasG12D/+Pdx-1-Cre murine modelsCANCER LETTERS2023-02-01通讯作者
70Primary tumor resection enhances the survival of pancreatic neuroendocrine carcinoma patients with liver metastasis under the definition of 2019 WHO classificationJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY2023-05-15通讯作者
71Prognostic value of preoperative [68 Ga]Ga-FAPI-04 PET/CT in patients with resectable pancreatic ductal adenocarcinoma in correlation with immunohistological characteristicsEUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING2023-01-25通讯作者
72Is neoadjuvant chemoradiotherapy for pancreatic cancer beneficial: A systematic review and meta-analysisFRONTIERS IN ONCOLOGY2022-11-23通讯作者
73Meta-analysis of robotic versus open pancreaticoduodenectomy in all patients and pancreatic cancer patientsFrontiers in Surgery2022-10-11通讯作者
74Targeting hypoxic tumor microenvironment in pancreatic cancerJournal of Hematology & Oncology2021-01-01通讯作者
75Do novel treatment strategies enhance T cell-mediated immunity: Opportunities and challenges in pancreatic cancer immunotherapyINTERNATIONAL IMMUNOPHARMACOLOGY2020-11-01通讯作者
76Current epidemiology of pancreatic cancer:challenges and opportunitiesChinese Journal of Cancer Research2020-10-01通讯作者
77Novel therapies targeting hypoxia mechanism to treat pancreatic cancerChinese Journal of Cancer Research2020-12-01通讯作者
78Win or loss? Combination therapy does improve the oncolytic virus therapy to pancreatic cancerCancer Cell International2022-04-07通讯作者
79MiR-135a biogenesis and regulation in malignancy: a new hope for cancer research and therapyCANCER BIOLOGY & MEDICINE2020-08-01通讯作者
80The prospect of serum and glucocorticoid-inducible kinase 1 (SGK1) in cancer therapy: a rising starTHERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY2020-07-01通讯作者
81Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC)CANCER LETTERS2020-10-01通讯作者
82Pancreatic head cancer: Open or minimally invasive pancreaticoduodenectomy?CHINESE JOURNAL OF CANCER RESEARCH2019-12-01通讯作者
83The dual functional role of MicroRNA-18a (miR-18a) in cancer developmentCLINICAL AND TRANSLATIONAL MEDICINE2019-12-01通讯作者
84Mechanistic target of rapamycin in the tumor microenvironment and its potential as a therapeutic target for pancreatic cancer.CANCER LETTERS2020-08-01通讯作者
85Novel discoveries targeting gemcitabine‐based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination?Cancer Medicine2019-10-01通讯作者
86Is Invagination Anastomosis More Effective in Reducing Clinically Relevant Pancreatic Fistula for Soft Pancreas After Pancreaticoduodenectomy Under Novel Fistula CriteriaFrontiers in Oncology2020-08-01通讯作者
87Novel therapeutic strategies and perspectives for metastatic pancreatic cancer: vaccine therapy is more than just a theoryCancer Cell International2020-03-04通讯作者
88Role of the microbiome in occurrence, development and treatment of pancreatic cancerMolecular Cancer2019-12-01通讯作者
89MicroRNA-27a (miR-27a) in Solid Tumors: A Review Based on Mechanisms and Clinical ObservationsFRONT ONCOL2019-09-01通讯作者
90The enhancement of glycolysis regulates pancreatic cancer metastasisCELLULAR AND MOLECULAR LIFE SCIENCES2019-08-20通讯作者
91Expression, function and clinical application of stanniocalcin-1 in cancerJOURNAL OF CELLULAR AND MOLECULAR MEDICINE2020-05-01通讯作者
92Comprehensive study of clinical features, prognostic factors, and survival in patients with pancreatic solid pseudopapillary neoplasms based on the 2019 WHO classificationJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY2023-07-21通讯作者
93Comparing the clinical value of baseline [68 Ga]Ga-FAPI-04 PET/CT and [18F]F-FDG PET/CT in pancreatic ductal adenocarcinoma: additional prognostic value of the distal pancreatitis.EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING2023-07-26通讯作者
94Local resection for solid pseudopapillary neoplasms of the pancreas shows improved postoperative gastrointestinal function and reduced mental stress: a multiquestionnaire survey from a large cohortInternational Journal of Surgery2023-12-01通讯作者
95Impact of Combined Chemotherapy and Targeted Therapy on Pancreatic Neuroendocrine Carcinoma with Liver Metastasis: A Single-Center Modified Nomogram AnalysisOncoTargets and Therapy2024-06-22通讯作者
96Human Equilibrative Nucleoside Transporter 1: Novel Biomarker and Prognostic Indicator for Patients with Gemcitabine-Treated Pancreatic CancerCancer Management and Research2024-05-21通讯作者
97FBXO32 Stimulates Protein Synthesis to Drive Pancreatic Cancer Progression and MetastasisCANCER RESEARCH2024-05-22通讯作者
98Multiomics integration reveals NETosis heterogeneity and TLR2 as a prognostic biomarker in pancreatic cancernpj Genomic Medicine2024-05-20通讯作者
99E3 ubiquitin ligase RBCK1 confers ferroptosis resistance in pancreatic cancer by facilitating MFN2 degradationFREE RADICAL BIOLOGY AND MEDICINE2024-05-18通讯作者
100The NF-κB/NUAK2 signaling axis regulates pancreatic cancer progression by targeting SMAD2/3iscience2024-04-19通讯作者
101Solid pseudopapillary neoplasm (SPN) of the pancreas: current understanding on its malignant potential and managementDiscover Oncology2024-03-18通讯作者
102Pancreatic ductal adenocarcinoma chemoresistance: From metabolism reprogramming to novel treatmentCHIN MED J2024-04-08通讯作者
103Ribosome profiling: a powerful tool in oncological researchBiomarker Research2024-01-25通讯作者
104The new era of pancreatic cancer treatment: Application of nanotechnology breaking through bottlenecksCANCER LETTERS2024-05-16通讯作者
105Epidemiology of pancreatic cancer: New version, new visionChinese Journal of Cancer Research2023-12-01通讯作者
106Organoid: Bridging the gap between basic research and clinical practiceCANCER LETTERS2023-12-18通讯作者
107Novel strategies optimize immunotherapy by improving the cytotoxic function of T cells for pancreatic cancer treatment.CANCER LETTERS2023-11-18通讯作者
108Regulatory role of RNA modifications in the treatment of pancreatic ductal adenocarcinoma (PDAC)HELIYON2023-10-17通讯作者
109From basic research to clinical application: targeting fibroblast activation protein for cancer diagnosis and treatmentCELLULAR ONCOLOGY2023-09-19通讯作者
110Cancer-associated fibroblasts: A key target to snatch victory from defeat in therapy resistance associated with the pancreatic cancer stroma.CANCER LETTERS2023-07-28通讯作者
  • 科研获奖Research Awards
# 获奖证书编号 奖项名称 获奖级别 获奖类别 获奖等级 获奖日期 颁奖单位 本单位是否为第一完成单位 完成单位排名 本人排序 备注
12015-254胰岛素瘤诊治体系的建立及临床应用省部级教育部高校科研成果奖(科学技术、人文社科)二等奖2016-02-26国家教育部12
22016-J-25301-2-01-R02胰岛素瘤诊治体系的建立及临床应用国家级国家最高科学技术奖、自然科学奖、技术发明奖、科技进步奖二等奖2016-12-21国家科技部12
32008-J-253-2-03-R03胰腺癌综合诊治方案的基础研究与临床应用国家级国家最高科学技术奖、自然科学奖、技术发明奖、科技进步奖二等奖2008-12-03国家科技部13
42015医-1-005-02胰岛素瘤诊治体系的建立及临床应用省部级科技进步奖、哲学社科奖一等奖2015-12-01北京市人民政府12
  • 研究成果Research Findings
# 成果类型 项目/专利/新品种名称
1作为主创人员获得授权的发明专利和新品种CHIP蛋白在胰腺癌治疗中的用途
2作为主创人员获得授权的发明专利和新品种CHIP蛋白在胰腺癌早期诊断以及预后判断中的用途
3作为主创人员获得授权的发明专利和新品种胰腺癌动物模型的构建方法
4作为主创人员获得授权的发明专利和新品种一种人胰腺癌组织类器官模型的构建方法
5出版高水平专著加速康复外科理论与实践
6出版高水平专著内分泌外科学
7出版高水平专著曾宪九胰腺病学
8出版高水平专著消化系统与疾病
9出版高水平专著外科学(第2版)
10出版高水平专著加速康复外科
11作为主创人员获得授权的发明专利和新品种一种人胰腺癌组织类器官模型的构建方法
12作为主创人员获得授权的发明专利和新品种一种用于胰腺癌早期诊断的生物标志物及应用
13作为主创人员获得授权的发明专利和新品种CHIP蛋白在胰腺癌治疗中的用途